Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT05195632 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05195632
- Sponsor
- Pierre Fabre Medicament
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-02
- Primary completion
- 2024-05-27
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.